SNIPE : First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System
Status: Recruiting.
This is a prospective, open label, multi center, single arm, first in human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumour resection. Up to 15 subjects (plus replacements) are enrolled in the study.
Subjects undergo ablation of the lung tumour via Irreversible Electroporation (IRE) method performed bronchoscopically, followed by resection of the tumour up to 19 days after the ablation.